Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness

被引:1
|
作者
Andersen, Lars v. B. [1 ,2 ]
Larsen, Martin J. [1 ,2 ]
Davies, Helen [3 ,4 ]
Degasperi, Andrea [3 ,4 ]
Nielsen, Henriette Roed [5 ]
Jensen, Louise A. [1 ,2 ]
Kroeldrup, Lone [1 ]
Gerdes, Anne-Marie [6 ]
Laenkholm, Anne-Vibeke [7 ]
Kruse, Torben A. [1 ,2 ]
Nik-Zainal, Serena [3 ,4 ,5 ]
Thomassen, Mads [1 ,2 ]
机构
[1] Odense Univ Hosp, Dept Clin Genet, Odense, Denmark
[2] Univ Southern Denmark, Clin Genome Ctr, Dept Clin Res, Odense, Denmark
[3] Univ Cambridge, Early Canc Inst, Hutchison Res Ctr, Cambridge Biomed Campus, Cambridge CB2 0XZ, England
[4] Addenbrookes Hosp, Addenbrookes Treatment Ctr Lv 6, Acad Lab Med Genet, Cambridge CB2 0QQ, England
[5] European Sperm Bank, Copenhagen, Denmark
[6] Copenhagen Univ Hosp Rigshospitalet, Dept Clin Genet, Copenhagen, Denmark
[7] Zealand Univ Hosp, Dept Surg Pathol, DK-4000 Roskilde, Denmark
关键词
Breast cancer; Hereditary breast cancer; Non-BRCA1; BRCA2; Whole genome sequencing; Mutational signatures; HRDetect; BRCAness; TUMOR MUTATIONAL BURDEN; BRCA2; MUTATIONS; DEFICIENCY; SIGNATURES; PREDICTOR; LANDSCAPE; GENES; TOOL;
D O I
10.1186/s13058-023-01655-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundFamilial breast cancer is in most cases unexplained due to the lack of identifiable pathogenic variants in the BRCA1 and BRCA2 genes. The somatic mutational landscape and in particular the extent of BRCA-like tumour features (BRCAness) in these familial breast cancers where germline BRCA1 or BRCA2 mutations have not been identified is to a large extent unknown.MethodsWe performed whole-genome sequencing on matched tumour and normal samples from high-risk non-BRCA1/BRCA2 breast cancer families to understand the germline and somatic mutational landscape and mutational signatures. We measured BRCAness using HRDetect. As a comparator, we also analysed samples from BRCA1 and BRCA2 germline mutation carriers.ResultsWe noted for non-BRCA1/BRCA2 tumours, only a small proportion displayed high HRDetect scores and were characterized by concomitant promoter hypermethylation or in one case a RAD51D splice variant previously reported as having unknown significance to potentially explain their BRCAness. Another small proportion showed no features of BRCAness but had mutationally active tumours. The remaining tumours lacked features of BRCAness and were mutationally quiescent.ConclusionsA limited fraction of high-risk familial non-BRCA1/BRCA2 breast cancer patients is expected to benefit from treatment strategies against homologue repair deficient cancer cells.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian
    Machackova, Eva
    Foretova, Lenka
    Lukesova, Mirka
    Vasickova, Petra
    Navratilova, Marie
    Coene, Ilse
    Pavlu, Hana
    Kosinova, Veronika
    Kuklova, Jitka
    Claes, Kathleen
    BMC CANCER, 2008, 8 (1)
  • [32] Identifying genomic rearrangements in BRCA1 and BRCA2 in high-risk individuals for hereditary breast and ovarian cancer
    Jackson, M.
    Mattair, D.
    Lin, H.
    Gutierrez-Barrera, A. M.
    Elsayegh, N.
    Litton, J. K.
    Hortobagyi, G. N.
    Arun, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
  • [33] The majority of 22 Dutch high-risk breast cancer families are due to either BRCA1 or BRCA2
    Peelen, T
    Cornelis, RS
    vanVliet, M
    PetrijBosch, A
    CletonJansen, AM
    MeijersHeijboer, H
    Klijn, JGM
    Vasen, HFA
    Cornelisse, CJ
    Devilee, P
    EUROPEAN JOURNAL OF HUMAN GENETICS, 1996, 4 (04) : 225 - 230
  • [34] Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families
    Angela G. Arnold
    Ebunoluwa Otegbeye
    Megan Harlan Fleischut
    Emily A. Glogowski
    Beth Siegel
    Sherry R. Boyar
    Erin Salo-Mullen
    Kim Amoroso
    Margaret Sheehan
    Janice L. Berliner
    Zsofia K. Stadler
    Noah D. Kauff
    Kenneth Offit
    Mark E. Robson
    Liying Zhang
    Breast Cancer Research and Treatment, 2014, 145 : 625 - 634
  • [35] Cancers in BRCA1 and BRCA2 Carriers and in Women at High Risk for Breast Cancer: MR Imaging and Mammographic Features
    Gilbert, Fiona J.
    Warren, Ruth M. L.
    Kwan-Lim, Gek
    Thompson, Deborah J.
    Eeles, Ros A.
    Evans, D. Gareth
    Leach, Martin O.
    RADIOLOGY, 2009, 252 (02) : 358 - 368
  • [36] Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource
    Mann, GJ
    Thorne, H
    Balleine, RL
    Butow, PN
    Clarke, CL
    Edkins, E
    Evans, GM
    Fereday, S
    Haan, E
    Gattas, M
    Giles, GG
    Goldblatt, J
    Hopper, JL
    Kirk, J
    Leary, JA
    Lindeman, G
    Niedermayr, E
    Phillips, KA
    Picken, S
    Pupo, GM
    Saunders, C
    Scott, CL
    Spurdle, AB
    Suthers, G
    Tucker, K
    Chenevix-Trench, G
    BREAST CANCER RESEARCH, 2006, 8 (01):
  • [37] ARRAY CGH ABERRATIONS IN NON-BRCA1/2 FAMILIAL BREAST CANCER
    Didraga, M.
    van Beers, E.
    Brandwijk, K.
    Joosse, S.
    Hogevorst, F.
    Wessels, L.
    Verhoef, S.
    Devilee, P.
    Nederlof, P. M.
    ANNALS OF ONCOLOGY, 2010, 21 : 29 - 30
  • [38] High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients
    Fackenthal, James D.
    Zhang, Jing
    Zhang, Bifeng
    Zheng, Yonglan
    Hagos, Fitsum
    Burrill, Devin R.
    Niu, Qun
    Huo, Dezheng
    Sveen, Walmy E.
    Ogundiran, Temidayo
    Adebamowo, Clemet
    Odetunde, Abayomi
    Falusi, Adeyinka G.
    Olopade, Olufunmilayo I.
    INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (05) : 1114 - 1123
  • [39] Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers
    Aaltonen, Kirsimari
    Blomqvist, Carl
    Amini, Rose-Marie
    Eerola, Hannaleena
    Aittomaki, Kristiina
    Heikkila, Paivi
    Nevanlinna, Heli
    CLINICAL CANCER RESEARCH, 2008, 14 (07) : 1976 - 1983
  • [40] A screen for germline mutations in the gene encoding CCCTC-binding factor (CTCF) in familial non-BRCA1/BRCA2 breast cancer
    Xiao-Lei Zhou
    Barbro Werelius
    Annika Lindblom
    Breast Cancer Research, 6